Literature DB >> 10083772

Progressive outer retinal necrosis syndrome as an early manifestation of human immunodeficiency virus infection.

C M Yang1, W W Wang, C P Lin.   

Abstract

Progressive outer retinal necrosis syndrome is a recently recognized variant of necrotizing herpetic retinopathy, developing in patients with acquired immune deficiency syndrome (AIDS) or other conditions causing immune compromise. We report a case in which the diagnosis of retinal necrosis syndrome was made before the diagnosis of AIDS was confirmed. A 41-year-old man presented with a 1-month history of blurred vision in his left eye. Ophthalmologic examination revealed extensive retinal necrosis with total retinal detachment in his left eye and multifocal deep retinal lesions scattered in the posterior fundus as well as in the peripheral retina in his right eye. The serologic test for human immunodeficiency virus (HIV) was positive. Despite intravenous acyclovir treatment for 1 week, the lesions in the right eye showed rapid progression. High doses of intravitreal ganciclovir were then given in addition to intravenous acyclovir. After combined treatment for 1 month, the lesions became quiescent and the visual acuity improved to 20/30. Although the patient soon developed full-blown AIDS, the vision in his right eye remained undisturbed. Physicians should suspect progressive outer retinal necrosis syndrome in any patient with rapidly progressive necrotizing retinopathy and test the patient for HIV infection. Aggressive combined antiviral agent therapy should be considered to save vision.

Entities:  

Mesh:

Year:  1999        PMID: 10083772

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  2 in total

1.  Progressive outer retinal necrosis: manifestation of human immunodeficiency virus infection.

Authors:  Phey Feng Lo; Rongxuan Lim; Serafeim N Antonakis; Goncalo C Almeida
Journal:  BMJ Case Rep       Date:  2015-05-06

Review 2.  Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection.

Authors:  Jairam R Lingappa; Connie Celum
Journal:  Drugs       Date:  2007       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.